Neuropsychological Outcomes From a Randomized Trial of Triple Intrathecal Chemotherapy Compared With 18 Gy Cranial Radiation As CNS Treatment in Acute Lymphoblastic Leukemia: Findings From Dana-Farber Cancer Institute ALL Consortium Protocol 95-01
J Clin Oncol Waber et al. 25:4914
Publisher’s Note
The November 1, 2007, article by Waber et al, entitled “Neuropsychological Outcomes From a Randomized Trial of Triple Intrathecal Chemotherapy Compared With 18 Gy Cranial Radiation As CNS Treatment in Acute Lymphoblastic Leukemia: Findings From Dana-Farber Cancer Institute ALL Consortium Protocol 95-01” (J Clin Oncol 25:4914–4921, 2007) was published online October 30, 2007, with dosing errors.
In the Abstract, Patients and Methods section, the radiation dose was given as 9 Gy in the first sentence, whereas it should have been .9 Gy, as follows:
“Between 1996 and 2000, 164 children with standard-risk ALL treated on Dana-Farber Cancer Institute Consortium Protocol 95-01 were randomly assigned to receive either 18 Gy CRT delivered in twice daily fractions (.9 Gy) with double IT therapy (methotrexate and cytarabine) or intensive triple IT drug (methotrexate, cytarabine and hydrocortisone) without CRT.”
In the Patients and Methods section of the text, under Treatment Protocols, the radiation dose was given as 9 Gy in the third sentence of the second paragraph, whereas it should have been .9 Gy, as follows:
“For CNS-directed therapy, standard-risk patients were randomly assigned to either intensive triple IT chemotherapy (methotrexate, cytarabine, and hydrocortisone) without CRT or 18 Gy CRT delivered in twice daily fractions (.9 Gy twice daily) with double IT therapy (methotrexate and cytarabine), both dosed according to age.”
These corrections have been made as of January 3, 2008.
|
